Geriatric Elements and Oral Anticoagulant Prescribing in Older Atrial Fibrillation Patients: SAGE‐AF

Oral anticoagulants are the cornerstone of stroke prevention in high‐risk patients with atrial fibrillation (AF). Geriatric elements, such as cognitive impairment and frailty, commonly occur in these patients and are often cited as reasons for not prescribing oral anticoagulants. We sought to systematically assess geriatric impairments in patients with AF and determine whether they were associated with oral anticoagulant prescribing.

[1]  L. Allen,et al.  Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation , 2019, American heart journal.

[2]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Heart rhythm.

[3]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Journal of the American College of Cardiology.

[4]  J. Díez-Manglano,et al.  Influence of frailty on anticoagulant prescription and clinical outcomes after 1-year follow-up in hospitalised older patients with atrial fibrillation , 2018, Internal and Emergency Medicine.

[5]  M. Turakhia,et al.  Predictors of oral anticoagulant non‐prescription in patients with atrial fibrillation and elevated stroke risk , 2018, American heart journal.

[6]  B. Gersh,et al.  Efficacy of Warfarin Anticoagulation and Incident Dementia in a Community‐Based Cohort of Atrial Fibrillation , 2018, Mayo Clinic proceedings.

[7]  R. Romero-Ortuño,et al.  Clinical frailty is independently associated with non‐prescription of anticoagulants in older patients with atrial fibrillation , 2017, Geriatrics & gerontology international.

[8]  G. Aksan,et al.  Real‐World Clinical Characteristics and Treatment Patterns of Individuals Aged 80 and Older with Nonvalvular Atrial Fibrillation: Results from the ReAl‐life Multicenter Survey Evaluating Stroke Study , 2017, Journal of the American Geriatrics Society.

[9]  D. Singer,et al.  Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke , 2017, Journal of the American Geriatrics Society.

[10]  C. Tannenbaum,et al.  The Effect of Bleeding Risk and Frailty Status on Anticoagulation Patterns in Octogenarians With Atrial Fibrillation: The FRAIL-AF Study. , 2016, The Canadian journal of cardiology.

[11]  R. Cumming,et al.  Atrial fibrillation in older inpatients: are there any differences in clinical characteristics and pharmacological treatment between the frail and the non‐frail? , 2016, Internal medicine journal.

[12]  L. Ngo,et al.  The Montreal Cognitive Assessment: Creating a Crosswalk with the Mini‐Mental State Examination , 2015, Journal of the American Geriatrics Society.

[13]  F. Puisieux,et al.  Underuse of Oral Anticoagulation for Individuals with Atrial Fibrillation in a Nursing Home Setting in France: Comparisons of Resident Characteristics and Physician Attitude , 2015, Journal of the American Geriatrics Society.

[14]  F. Maes,et al.  Risk scores and geriatric profile: can they really help us in anticoagulation decision making among older patients suffering from atrial fibrillation? , 2014, Clinical interventions in aging.

[15]  D. Singer,et al.  Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry , 2014, Circulation.

[16]  Donald R. Miller,et al.  Outcomes of Anticoagulation Therapy in Patients with Mental Health Conditions , 2014, Journal of General Internal Medicine.

[17]  D. Singer,et al.  Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. , 2013, The American journal of cardiology.

[18]  D. Alsop,et al.  Novel risk markers and long-term outcomes of delirium: the successful aging after elective surgery (SAGES) study design and methods. , 2012, Journal of the American Medical Directors Association.

[19]  G. Lip,et al.  Use of the CHA2DS2-VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation , 2012, Circulation.

[20]  J. Cornuz,et al.  Risk of falls and major bleeds in patients on oral anticoagulation therapy. , 2012, The American journal of medicine.

[21]  Stanley Nattel,et al.  Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. , 2012, The Canadian journal of cardiology.

[22]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[23]  John Spertus,et al.  Development and Validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in Patients With Atrial Fibrillation , 2011, Circulation. Arrhythmia and electrophysiology.

[24]  G. Lip,et al.  Underuse of oral anticoagulants in atrial fibrillation: a systematic review. , 2010, The American journal of medicine.

[25]  B. Horne,et al.  Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. , 2010, Heart rhythm.

[26]  M. Boustani,et al.  Impact and recognition of cognitive impairment among hospitalized elders. , 2010, Journal of hospital medicine.

[27]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[28]  C. Blaum,et al.  Comparing Models of Frailty: The Health and Retirement Study , 2009, Journal of the American Geriatrics Society.

[29]  S. Matthews,et al.  The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. , 2008, Age and ageing.

[30]  A. Localio,et al.  Risk factors for nonadherence to warfarin: results from the IN‐RANGE study , 2008, Pharmacoepidemiology and drug safety.

[31]  G. Lip,et al.  Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.

[32]  R. Spitzer,et al.  The PHQ-9 , 2001, Journal of General Internal Medicine.

[33]  S. Black,et al.  National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards , 2006, Stroke.

[34]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[35]  T. Egberts,et al.  Cognitive Impairment as Determinant for Sub-Optimal Control of Oral Anticoagulation Treatment in Elderly Patients with Atrial Fibrillation , 2005, Drugs & aging.

[36]  D. Leys,et al.  Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. , 2004, British journal of clinical pharmacology.

[37]  L. Fried,et al.  Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[38]  O. Benavente,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.

[39]  C. Sherbourne,et al.  The MOS social support survey. , 1991, Social science & medicine.